Clinical Outcomes of Truncated Antimicrobial Therapy for Community-Acquired Pneumonia

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Annals of Internal Medicine https://doi.org/10.7326/ANNALS-25-03538
Dr.  George Doumat et al.

Points

Researchers conducted a multicenter target trial emulation across sixty-seven hospitals to compare the effectiveness of short-course antibiotics against traditional regimens for patients hospitalized with community-acquired pneumonia.
The study found that only ten percent of hospitalized adults met the strict clinical criteria for early stability necessary to safely qualify for a three-day antibiotic treatment course.
Data indicated that there were no meaningful differences in mortality or hospital readmission rates between those receiving shorter courses and patients treated for five days or longer.
Investigators observed that the incidence of urgent care visits and secondary infections like C. difficile remained comparable regardless of whether the patient received a short or long duration.
These results suggest that clinicians can safely utilize shorter antibiotic durations for a select subset of stable patients to improve antimicrobial stewardship and reduce unnecessary healthcare resource utilization.

Summary

This study evaluated the safety and efficacy of short-course antibiotic therapy for adults hospitalized with community-acquired pneumonia (CAP) who demonstrated early clinical stability. Utilizing a target trial emulation across 67 Michigan hospitals between 2017 and 2024, researchers compared clinical outcomes between patients receiving a three- to four-day antibiotic course and those receiving a traditional duration of five days or longer. The investigation sought to determine if reduced exposure to antimicrobials could maintain non-inferior health outcomes in a specifically screened subset of hospitalized patients.

The analysis revealed that only 10% of the total patient population met the stringent criteria for early clinical stability required for short-course eligibility. Among this subset, the findings demonstrated no meaningful statistical differences in primary safety and efficacy endpoints. Specifically, outcomes regarding 30-day mortality, hospital readmissions, and post-discharge urgent care visits were similar across both treatment arms. Furthermore, the incidence of secondary complications, such as Clostridioides difficile infections, remained comparable, suggesting that truncated regimens do not increase the risk of adverse clinical events in stable patients.

These results suggest that for a highly selected group of hospitalized CAP patients, a three- to four-day antibiotic course is as effective as longer durations. While the study supports the principles of antimicrobial stewardship by reducing unnecessary drug exposure, the authors noted that the limited number of short-course cases necessitates larger prospective trials to confirm these findings across broader demographics. The study provides a preliminary framework for clinicians to identify candidates for early discontinuation of therapy, potentially reducing healthcare costs and the risk of antimicrobial resistance without compromising patient safety.

Link to the article: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2847656

References

Doumat, G., Ratz, D., Horowitz, J. K., Gandhi, T. N., Petty, L. A., Malani, A. N., Osterholzer, D., Misra, P., Gupta, A. B., Flanders, S. A., & Vaughn, V. M. (2026). Short versus longer antibiotic duration for community-acquired pneumonia: A multicenter target trial emulation. Annals of Internal Medicine, ANNALS-25-03538. https://doi.org/10.7326/ANNALS-25-03538